ArticleFrontiers in oncology2026
Warning of the poor effect of chemotherapy: primary gastric malignant melanoma misdiagnosed as "gastric adenocarcinoma": a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary gastric melanoma is a rare clinical finding. Its diagnosis can be challenging due to the complex tissue structure of the stomach and the diverse morphology of melanoma cells, which contribute to the increased likelihood of misdiagnosis. Here we report a 69-year-old female patient with primary gastric melanoma, initially misdiagnosed as "gastric adenocarcinoma". The patient initially received two cycles of neoadjuvant therapy with Tegeo in combination with oxaliplatin (SOX). Unfortunately, the response was not satisfactory. In order to guide further treatment decisions, immunohistochemistry (IHC) and next-generation sequencing (NGS) were conducted. Immunohistochemistry: CK (-), CK8/18 (-), Vimentin (+), CD56 (-), CgA (-), Syn (-), ALK (-), CD30 (-), S-100 (+), INI1 (expression), CD43 (-), CD3 (-), CD20 (-), Brg-1 (expression), CD117 (-), DOG-1 (-), CD34 (-), HMB-45 (+), melan-A (+), Her-2 (-). NGS showed no significant abnormalities in HER-2 and wild type in the range of BRAF gene detection. Through a Multidisciplinary Team (MDT) consultation, she was finally diagnosed with "primary gastric malignant melanoma". Despite the disease progressing after first-line chemotherapy with temozolomide, cisplatin, and bevacizumab, a second-line treatment with albumin paclitaxel, carboplatin, and bevacizumab resulted in a sustained partial remission (PR). The patient's condition was stable during the follow-up period. As far as we know, this is a rare case of primary gastric malignant melanoma which received persistent PR after second-line treatment. Combined with the pathological manifestations of MM and recent clinical studies, the pathological features and treatment of primary gastric malignant melanoma were discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.